Skip to main content
News

News

DENT Named First Site for DelMar Pharmaceuticals' STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

Posted on: 07/21/2017

DENT Neurologic Institute was named the first site for DelMar Pharmaceuticals' STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM. Site initiation visits are usually the final step before patient enrollment. Dr. Laszlo Mechtler, Medical Director at DENT, will be acting as principal investigator of the trial.

To learn more about this exciting new trial visit DelMar Pharmaceuticals

Back to Article List